Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer

Nouso, Kazuhiro; Amano, Maho; Ito, Yoichi M.; Miyahara, Koji; Morimoto, Yuki; Kato, Hironari; Tsutsumi, Keisuke; Tomoda, Takeshi; Yamamoto, Naoki; Nakamura, Shinichiro; Kobayashi, Sayo; Kuwaki, Kenji; Hagihara, Hiroaki; Onishi, Hideki; Miyake, Yasuhiro; Ikeda, Fusao; Shiraha, Hidenori; Takaki, Akinobu; Nakahara, Taku; Nishimura, Shin Ichiro; Yamamoto, Kazuhide

doi:10.1007/s00535-012-0732-7

Cited by 53 publications

(57 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aberrant glycosylation of serum proteins is observed in sera of patients with various types of cancer, including colon cancer, ovarian cancer, and pancreatic cancer [9e12]. We reported previously that multibranch antennary and fucosylated glycan was elevated in pancreatic cancer and hepatocellular carcinoma [13,14]. Although these changes might occur in patients with invasive IPMNs, the serum glycome profile of these patients has not been investigated.…”

Section: Introductionmentioning

confidence: 97%

Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas

Akimoto¹,

Nouso²,

Kato³

et al. 2015

Pancreatology

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 97%

Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas

Akimoto¹,

Nouso²,

Kato³

et al. 2015

Pancreatology

Self Cite

View full text Add to dashboard Cite

“…Recently, glycosylation of IgG, which influences IgG effector function, has been reported to be associated with the prognosis of malignant tumors including pancreatic cancer [23,24]. This indicates that serum IgG of cancer patients may contain some autoantibodies associated with the disease progression, and autologous tumor can become a target of anti-tumor immune response in vivo.…”

Section: Discussionmentioning

confidence: 99%

Serum Anti-60S Ribosomal Protein L29 Antibody as a Novel Prognostic Marker for Unresectable Pancreatic Cancer

Muro¹,

Miyake²,

Kato³

et al. 2015

Digestion

Self Cite

View full text Add to dashboard Cite

Background/Aims: Recently, we found the presence of anti-60S ribosomal protein L29 antibody (anti-RPL29) in human sera, inhibiting the proliferation of pancreatic cancer cells in vitro. We aimed to estimate the association of serum anti-RPL29 levels with clinical features in patients affected with unresectable pancreatic cancer. Methods: We retrospectively reviewed 105 patients with unresectable pancreatic cancer. Serum anti-RPL29 levels were measured by the indirect enzyme-linked immunosorbent assay. The cut-off was represented by the 95th percentile in 62 healthy volunteers. Results: Median survival time (MST) was 11.1 months in 49 patients showing serum anti-RPL29 level >cut-off and 7.4 months in 56 patients showing serum anti-RPL29 level ≤cut-off. In locally advanced disease, MST was 17.9 months in 22 patients showing serum anti-RPL29 level >cut-off and 10.0 months in 19 patients showing serum anti-RPL29 level ≤cut-off. In metastatic disease, MST was 8.7 months in 27 patients showing serum anti-RPL29 level >cut-off and 5.9 months in 37 patients showing serum anti-RPL29 level ≤cut-off. In the multivariate Cox proportional hazard model, serum anti-RPL29 level >cut-off, abdominal or back pain, performance status, and metastatic disease were identified as independent prognostic factors. Conclusion: Serum anti-RPL29 levels may be a novel candidate for a prognostic marker for unresectable pancreatic cancer.

show abstract

“…A 10-µL aliquot of the purified Igs fractions were analyzed using the glycoblotting method [11,12,15,33] on a Sweetblot instrument (System Instruments, Hachioji, Tokyo, Japan). Then, the resulting benzyloxiamine (BOA)-labelled glycans were detected by matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass spectrometry (Ultraflex 3 TOF/TOF mass spectrometer; Bruker Daltonics, Bremen, Germany) ( Figure A1a-f).…”

Section: Serum N-glycomics Of Igs Performed By Using the Glycoblottinmentioning

confidence: 99%

Aberrant N-glycosylation profile of serum immunoglobulins is a diagnostic biomarker of urothelial carcinomas

Tanaka¹,

Yoneyama²,

Noro³

et al. 2018

European Urology Supplements

View full text Add to dashboard Cite

Abstract:The aim of this study to determine whether the aberrant N-glycosylated serum immunoglobulins (Igs) can be applied as a diagnostic marker of urothelial carcinoma (UC). Between 2009 and 2016, we randomly obtained serum available from 237 UC and also 96 prostate cancer as other cancer controls from our serum bank and also obtained-from 339 healthy volunteers (HV)-controls obtained from community-dwelling volunteers in Iwaki Health Promotion Project. A total of 32 types of N-glycan levels on Igs were determined by high-throughput N-glycomics and analyzed by multivariable discriminant analysis. We found five UC-associated aberrant N-glycans changes on Igs and also found that asialo-bisecting GlcNAc type N-glycan on Igs were significantly accumulated in UC patients. The diagnostic N-glycan Score (dNGScore) established by combination of five N-glycans on Igs discriminated UC patients from HV and prostate cancer (PC) patients with 92.8% sensitivity and 97.2% specificity. The area under the curve (AUC) for of the dNGScore was 0.969 for UC detection that was much superior to that of urine cytology (AUC, 0.707) and hematuria (AUC, 0.892). Furthermore, dNGScore can detect hematuria and urine cytology negative patients. The dNGscore based on aberrant N-glycosylation signatures of Igs were found to be promising diagnostic biomarkers of UCs.

show abstract

Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer

Abstract: Comprehensive glycome analysis can be used to know the presence of pancreatic cancer, distant metastasis, and patient prognosis, simultaneously.

Cited by 53 publications

References 23 publications

Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas

Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas

Serum Anti-60S Ribosomal Protein L29 Antibody as a Novel Prognostic Marker for Unresectable Pancreatic Cancer

Aberrant N-glycosylation profile of serum immunoglobulins is a diagnostic biomarker of urothelial carcinomas

Contact Info

Product

Resources

About